BR112022007595A2 - Métodos para tratar doença de alzheimer - Google Patents
Métodos para tratar doença de alzheimerInfo
- Publication number
- BR112022007595A2 BR112022007595A2 BR112022007595A BR112022007595A BR112022007595A2 BR 112022007595 A2 BR112022007595 A2 BR 112022007595A2 BR 112022007595 A BR112022007595 A BR 112022007595A BR 112022007595 A BR112022007595 A BR 112022007595A BR 112022007595 A2 BR112022007595 A2 BR 112022007595A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- methods
- treat alzheimer
- alzheimer
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924633P | 2019-10-22 | 2019-10-22 | |
| PCT/US2020/056676 WO2021081101A1 (en) | 2019-10-22 | 2020-10-21 | Anti-beta-amyloid antibody for treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022007595A2 true BR112022007595A2 (pt) | 2022-08-23 |
Family
ID=73344157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022007595A BR112022007595A2 (pt) | 2019-10-22 | 2020-10-21 | Métodos para tratar doença de alzheimer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220372123A1 (https=) |
| EP (1) | EP4048695A1 (https=) |
| JP (2) | JP2022553329A (https=) |
| KR (1) | KR20220084095A (https=) |
| CN (1) | CN114599393A (https=) |
| AU (1) | AU2020371612A1 (https=) |
| BR (1) | BR112022007595A2 (https=) |
| CA (1) | CA3158513A1 (https=) |
| CO (1) | CO2022004902A2 (https=) |
| IL (1) | IL292363A (https=) |
| JO (1) | JOP20220092A1 (https=) |
| MX (1) | MX2022004678A (https=) |
| WO (1) | WO2021081101A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2019152706A1 (en) | 2018-01-31 | 2019-08-08 | Alector Llc | Anti-ms4a6a antibodies and methods of use thereof |
| US11472874B2 (en) | 2018-01-31 | 2022-10-18 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| TW202300517A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202300518A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2023081194A2 (en) * | 2021-11-03 | 2023-05-11 | Biogen Ma Inc. | Methods for treating alzheimer's disease |
| AU2022439338A1 (en) * | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| WO2024086796A1 (en) * | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| US20240207362A1 (en) * | 2022-10-25 | 2024-06-27 | Institute For Basic Science (Ibs) | Extracranial Methods For Facilitating Cerebrospinal Fluid Drainage |
| EP4455161A1 (en) | 2023-04-24 | 2024-10-30 | ONO Pharmaceutical Co., Ltd. | Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies |
| TW202530246A (zh) | 2023-09-15 | 2025-08-01 | 愛爾蘭商歐賽爾普羅希那有限公司 | 細胞穿透劑及其用途 |
| WO2025117721A1 (en) * | 2023-11-27 | 2025-06-05 | Massachusetts Institute Of Technology | Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081008A1 (en) | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| WO2008141321A1 (en) * | 2007-05-14 | 2008-11-20 | Medtronic, Inc. | Methods and device to neutralize soluble toxic agents in the brain |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2598882B1 (en) * | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
| ME03008B (me) * | 2011-09-19 | 2018-10-20 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti |
| US20150315267A1 (en) * | 2012-12-07 | 2015-11-05 | Thierry Bussiere | A method of reducing brain amyloid plaques using anti-ab antibodies |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CN114796481A (zh) * | 2016-06-07 | 2022-07-29 | 生物基因国际神经科学有限责任公司 | 治疗阿尔茨海默病的方法 |
-
2020
- 2020-10-21 KR KR1020227015913A patent/KR20220084095A/ko active Pending
- 2020-10-21 AU AU2020371612A patent/AU2020371612A1/en active Pending
- 2020-10-21 US US17/770,997 patent/US20220372123A1/en active Pending
- 2020-10-21 CA CA3158513A patent/CA3158513A1/en active Pending
- 2020-10-21 CN CN202080073830.0A patent/CN114599393A/zh active Pending
- 2020-10-21 IL IL292363A patent/IL292363A/en unknown
- 2020-10-21 EP EP20804740.7A patent/EP4048695A1/en active Pending
- 2020-10-21 JP JP2022523595A patent/JP2022553329A/ja active Pending
- 2020-10-21 BR BR112022007595A patent/BR112022007595A2/pt unknown
- 2020-10-21 MX MX2022004678A patent/MX2022004678A/es unknown
- 2020-10-21 WO PCT/US2020/056676 patent/WO2021081101A1/en not_active Ceased
-
2022
- 2022-04-19 CO CONC2022/0004902A patent/CO2022004902A2/es unknown
- 2022-04-20 JO JOP/2022/0092A patent/JOP20220092A1/ar unknown
-
2025
- 2025-10-27 JP JP2025181171A patent/JP2026012271A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021081101A1 (en) | 2021-04-29 |
| IL292363A (en) | 2022-06-01 |
| AU2020371612A1 (en) | 2022-05-19 |
| CA3158513A1 (en) | 2021-04-29 |
| JP2026012271A (ja) | 2026-01-23 |
| CO2022004902A2 (es) | 2022-07-08 |
| KR20220084095A (ko) | 2022-06-21 |
| JOP20220092A1 (ar) | 2023-01-30 |
| CN114599393A (zh) | 2022-06-07 |
| EP4048695A1 (en) | 2022-08-31 |
| US20220372123A1 (en) | 2022-11-24 |
| MX2022004678A (es) | 2022-08-15 |
| JP2022553329A (ja) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022007595A2 (pt) | Métodos para tratar doença de alzheimer | |
| MX2025010483A (es) | Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
| BR112022000231A2 (pt) | Novos métodos | |
| BR112015005117A2 (pt) | métodos de tratamento da doença de alzheimer e suas composições farmacêuticas | |
| EA202092154A1 (ru) | Комбинированная терапия | |
| BR112018075300A2 (pt) | métodos para tratamento do mal de alzheimer | |
| BR112018073843A2 (pt) | anticorpos de peptídeo beta amiloide anti-n3pglu e usos dos mesmos | |
| BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase | |
| EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| BR112021011729A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
| BR112023017367A2 (pt) | Composições e métodos para inibição de ceto-hexoquinase (khk) | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| BR112019001193A2 (pt) | uso de sulfatos de colesterol oxigenados (ocs) para tratar doença de pele inflamatória e lesões de pele | |
| BR112017022653A2 (pt) | ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph? | |
| AR119159A1 (es) | Tratamientos de angioedema | |
| BR112017013674A2 (pt) | métodos e composições para tratamento de doenças cerebrais. | |
| BR112022007010A2 (pt) | Terapia gênica para doença de alzheimer | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| BR112021019854A2 (pt) | Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares | |
| BR112021025383A2 (pt) | Metiltionínio para uso no tratamento de sinaptopatias | |
| BR112019011350A2 (pt) | terapia de combinação |